Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences, Inc. develops clinical-stage therapeutics that modulate lipid-signaling pathways, including programs tied to the endocannabinoid system and fatty acid-binding proteins. Company news commonly covers pipeline updates for ART27.13 and ART26.12, including cancer anorexia-cachexia, neuropathic pain, glaucoma, dermatologic, neurological and other inflammation-related indications.
Recurring developments include FABP5 inhibitor research, peer-reviewed publications, collaborations using biological-data analysis, preclinical and clinical program disclosures, patent activity, and externally funded studies. Artelo news also includes capital-structure actions such as private placements, common stock and warrant offerings, and Nasdaq listing-compliance matters.
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has announced a proposed underwritten public offering of common stock and/or pre-funded warrants. The offering will be managed by R.F. Lafferty & Co., Inc. as the sole book-running manager.
The securities will be offered through a "shelf" registration statement on Form S-3 that was previously filed and declared effective by the SEC on July 14, 2023. The final terms, size, and completion of the offering will depend on market conditions.
Artelo Biosciences (Nasdaq: ARTL) presented positive interim Phase 2 CAReS data for ART27.13 at the 2025 Cancer Cachexia Society Conference. The drug, targeting cancer anorexia-cachexia syndrome (CACS), demonstrated significant benefits in key metrics:
Patients receiving the highest dose (1300 µg) achieved an average +6% weight gain over 12 weeks, while placebo patients lost ~5%. The treatment showed improvements in lean body mass and increased daily activity levels, confirmed through digital wearable data. The drug maintained a favorable safety profile with mostly mild to moderate adverse events and no serious drug-related incidents.
Professor Barry Laird from Oslo University Hospital presented the data, while the company engaged in partnering discussions to advance the program's commercial potential.
Artelo Biosciences (Nasdaq: ARTL) has published significant preclinical data for ART12.11, their proprietary CBD:TMP cocrystal, demonstrating superior efficacy in treating stress-induced depression and anxiety compared to CBD alone. The study, published in Progress in Neuro-Psychopharmacology and Biological Psychiatry, revealed that ART12.11 achieved higher plasma concentrations and enhanced activation of endocannabinoid and serotonergic systems in key brain regions.
The research, conducted with Western Ontario University, showed ART12.11 reversed stress-induced behavioral deficits more effectively than CBD alone, TMP alone, or their non-crystalline mixture. Importantly, the MHRA has agreed to allow Artelo to leverage existing CBD and TMP data for their clinical trial application, potentially accelerating the pathway to human trials planned for next year.
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has completed its previously announced public offering, raising $3.0 million in gross proceeds. The offering consisted of 640,924 shares of common stock priced at $4.40 per share and pre-funded warrants to purchase 40,894 shares at $4.399 per warrant.
The company granted underwriters a 45-day option to purchase up to an additional 102,272 shares to cover over-allotments. R. F. Lafferty & Co. served as the sole book-running manager for the offering, which was conducted under Artelo's shelf registration statement.
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has announced the pricing of a $3.0 million public offering. The offering consists of 640,924 shares of common stock priced at $4.40 per share and pre-funded warrants to purchase up to 40,894 shares at $4.399 per warrant.
The company has granted underwriters a 45-day option to purchase up to an additional 102,272 shares. R.F. Lafferty & Co. is serving as the sole book-running manager. The offering, expected to close on September 5, 2025, is being made through a shelf registration statement previously filed with the SEC.
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has announced the commencement of an underwritten public offering of common stock and/or pre-funded warrants. The offering will be managed by R.F. Lafferty & Co., Inc. as the sole book-running manager.
The securities will be offered through a "shelf" registration statement previously filed with the SEC (File No. 333-273153) and declared effective on July 14, 2023. The company focuses on developing treatments for cancer, pain, dermatologic, and neurological conditions through lipid-signaling pathway modulation.
Artelo Biosciences (Nasdaq: ARTL) has announced positive interim Phase 2 CAReS trial results for ART27.13, their treatment candidate for cancer anorexia-cachexia syndrome (CACS). The trial demonstrated significant improvements in weight, lean body mass, and activity in treated patients.
CACS affects up to 80% of cancer patients and currently has no FDA-approved treatment. Following these promising results and strong interest from multiple pharmaceutical companies, Artelo is actively pursuing partnership opportunities for ART27.13's development, stating they won't need to internally fund Phase 3 trials.
The company believes a licensing transaction represents the most value-accretive path forward for shareholders in this multi-billion-dollar potential market.
Artelo Biosciences (Nasdaq: ARTL) announced encouraging interim results from its Phase 2 Cancer Appetite Recovery Study (CAReS) trial for ART27.13, a treatment for cancer anorexia-cachexia syndrome (CACS). The study showed significant positive outcomes, with patients receiving the 1300 microgram dose achieving a +6.38% mean weight gain after 12 weeks, compared to -5.42% loss in placebo group.
Key highlights include a +4.23% increase in lean body mass at one month for treated patients, while placebo patients lost -3.15%. The drug demonstrated a favorable safety profile with mostly mild to moderate adverse events. The positive results are accelerating Artelo's partnering discussions with pharmaceutical companies for ART27.13, which targets CACS, a condition affecting up to 80% of cancer patients with no current FDA-approved treatment.
Artelo Biosciences (Nasdaq: ARTL) has announced positive results from its preliminary food effect evaluation of ART26.12, their novel non-opioid pain treatment candidate. The assessment was conducted as part of their successful Phase 1 single ascending dose (SAD) clinical trial.
The study demonstrated favorable safety outcomes with no serious adverse events reported. Key findings showed consistent exposure levels under fasted conditions with low inter-subject variability, indicating ART26.12 can be effectively administered with or without food. The drug showed predictable pharmacokinetics and a benign safety profile, crucial characteristics for a chronic pain treatment.
The company is now preparing to advance to a multiple ascending dose (MAD) study, scheduled to begin in Q4 2025, to further evaluate safety, tolerability, and pharmacokinetics with repeated dosing.
Artelo Biosciences (Nasdaq: ARTL) reported Q2 2025 financial results and provided updates on its clinical pipeline. The company highlighted successful completion of Phase 1 Single Ascending Dose study for ART26.12 with positive safety results and is preparing for Multiple Ascending Dose study in Q4 2025.
Key financial metrics include Q2 net loss of $3.2 million ($5.61 per share), R&D expenses of $1.9 million, and cash position of $2.1 million. The company secured additional funding through convertible notes ($0.9M) and two PIPE transactions totaling $10.9 million.
Artelo expects multiple clinical data readouts in Q3 2025, including Phase 2 results from the CAReS study of ART27.13 for cancer anorexia-cachexia syndrome. The company also presented promising preclinical data for ART12.11 in depression treatment and plans first-in-human studies in early 2026.